Purchase Order 75N91018P00509

<p>The National Cancer Institute awarded a purchase order to Genewiz, LLC for sequencing services valued at $5,148.00, with an award date of May 16, 2018 and completion deadline of June 14, 2018. Work is performed at Genewiz's facility in South Plainfield, New Jersey. The order is priced firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Macrogen Clinical Laboratory, Inc. for whole genome sequencing (30X) on November 29, 2017, with a ceiling value of $22,485.00. Performance occurs in Bethesda, Maryland, with an ultimate completion date of January 31, 2018. The order is firm fixed price and carries no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,484.18 on August 12, 2019, for sequencing services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and is scheduled for completion by September 11, 2019.</p>

<p>The National Cancer Institute issued a $2,675 delivery order to Genewiz, LLC on August 31, 2019, under the NCI Genomic Characterization Centers IDIQ for genomic characterization services supporting the Center for Cancer Genomics.</p> <p>The NCI Genomic Characterization Centers IDIQ provides cancer genomics capabilities to the National Cancer Institute. Place of performance is South Plainfield, NJ. The order was firm fixed price with an ultimate completion date of August 30, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $12,068.21, with an award date of September 12, 2019 and completion date of October 12, 2019. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,823.88 on July 24, 2019. The order covers sequencing services at the awardee's location in Piscataway, New Jersey, with an ultimate completion date of August 23, 2019. Pricing is firm fixed price with no set-aside applied.</p>

Genewiz, LLC, a subsidiary of Azenta, Inc., was awarded a $4,997.50 firm fixed-price call under a Blanket Purchase Agreement (BPA) by the National Cancer Institute for sequencing reactions services. The contract, issued on November 2, 2015, with an ultimate completion date of September 30, 2017, was performed at Genewiz's facility in South Plainfield, New Jersey. No set-aside designation was used for this award. This BPA call represents a task order for genomic sequencing services that aligns...

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for sequencing services valued at $14,558.16, issued on January 14, 2020, with final completion due February 12, 2020. Work is performed in Bethesda, Maryland. The order carries firm fixed pricing and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to GenScript USA Inc. for $6,126.56 on July 28, 2017, for sequencing services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. valued at $14,075.00 on November 30, 2018. Performance occurs in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of December 30, 2018.</p>